{
    "Trade/Device Name(s)": [
        "CALPREST",
        "Calprest Fecal calprotectin immunological test system"
    ],
    "Submitter Information": "Eurospital S.p.A.",
    "510(k) Number": "K130945",
    "Predicate Device Reference 510(k) Number(s)": [
        "K050007"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NXO"
    ],
    "Summary Letter Date": "January 16, 2014",
    "Summary Letter Received Date": "December 12, 2013",
    "Submission Date": "December 11, 2013",
    "Regulation Number(s)": [
        "21CFR866.5180"
    ],
    "Regulation Name(s)": [
        "Fecal calprotectin immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Calprotectin"
    ],
    "Specimen Type(s)": [
        "Stool"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "96 well microtiter plate"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme-linked immunosorbent assay (ELISA)",
        "Colorimetric detection"
    ],
    "Methodologies": [
        "Quantitative ELISA"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for CALPREST quantitative ELISA for measuring fecal calprotectin to aid diagnosis of IBD and differentiation from IBS.",
    "Indications for Use Summary": "Quantitative ELISA to aid in diagnosing inflammatory bowel diseases (IBD, Crohn's disease, ulcerative colitis) and to differentiate IBD from irritable bowel syndrome (IBS) in conjunction with other clinical and laboratory findings.",
    "fda_folder": "Immunology"
}